Literature DB >> 9343807

Estimating CE ratios under second-order uncertainty: the mean ratio versus the ratio of means.

A A Stinnett1, A D Paltiel.   

Abstract

Two methods have been presented for estimating cost-effectiveness ratios under conditions of second-order (model) uncertainty: one method estimates a mean ratio of cost to effect (the "mean ratio" approach), and the other estimates a ratio of mean cost to mean effect (the "ratio of means" approach). However, the question of which estimate is theoretically correct has not been formally addressed. The authors show that the "ratio of means" approach follows directly from the theoretical foundations of cost-effectiveness analysis, has attractive internal consistency properties, and is consistent with a simple vector algebra approach to the problem. In contrast, the "mean ratio" approach has not been shown to follow from first principles, is internally inconsistent, and can prescribe economically inefficient choices. It is concluded that the "ratio of means" procedure should be preferred unless persuasive arguments are presented to the contrary.

Mesh:

Year:  1997        PMID: 9343807     DOI: 10.1177/0272989X9701700414

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  32 in total

Review 1.  Assessing quality in decision analytic cost-effectiveness models. A suggested framework and example of application.

Authors:  M Sculpher; E Fenwick; K Claxton
Journal:  Pharmacoeconomics       Date:  2000-05       Impact factor: 4.981

Review 2.  Handling uncertainty in cost-effectiveness models.

Authors:  A H Briggs
Journal:  Pharmacoeconomics       Date:  2000-05       Impact factor: 4.981

3.  Revisiting United States valuation of EQ-5D states.

Authors:  Benjamin M Craig; Jan J V Busschbach
Journal:  J Health Econ       Date:  2011-07-21       Impact factor: 3.883

4.  Incorporation of uncertainty in health economic modelling studies.

Authors:  Anthony O'Hagan; Christopher McCabe; Ron Akehurst; Alan Brennan; Andrew Briggs; Karl Claxton; Elisabeth Fenwick; Dennis Fryback; Mark Sculpher; David Spiegelhalter; Andrew Willan
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

5.  Presenting evidence and summary measures to best inform societal decisions when comparing multiple strategies.

Authors:  Simon Eckermann; Andrew R Willan
Journal:  Pharmacoeconomics       Date:  2011-07       Impact factor: 4.981

6.  Valuing Healthcare Goods and Services: A Systematic Review and Meta-Analysis on the WTA-WTP Disparity.

Authors:  Adriënne H Rotteveel; Mattijs S Lambooij; Nicolaas P A Zuithoff; Job van Exel; Karel G M Moons; G Ardine de Wit
Journal:  Pharmacoeconomics       Date:  2020-05       Impact factor: 4.981

7.  Optimal Cervical Cancer Screening in Women Vaccinated Against Human Papillomavirus.

Authors:  Jane J Kim; Emily A Burger; Stephen Sy; Nicole G Campos
Journal:  J Natl Cancer Inst       Date:  2016-10-18       Impact factor: 13.506

8.  From a different angle: a novel approach to health valuation.

Authors:  Benjamin M Craig; Mark Oppe
Journal:  Soc Sci Med       Date:  2009-10-31       Impact factor: 4.634

9.  Potential cost-effectiveness of a family-based program in mild Alzheimer's disease patients.

Authors:  Janne Martikainen; Hannu Valtonen; Tuula Pirttilä
Journal:  Eur J Health Econ       Date:  2004-06

Review 10.  Minimal Residual Disease Evaluation in Childhood Acute Lymphoblastic Leukemia: An Economic Analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2016-03-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.